(Q36249234)

13 August 2017

1 reference

title

Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer (English)

1 reference

13 August 2017

1 reference

Wendy L Allen

1

1 reference

PubMed ID

16143000

13 August 2017

Patrick G Johnston

series ordinal

2

1 reference

13 August 2017

1 September 2005

1 reference

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

603-614

1 reference

13 August 2017

6

1 reference

Capecitabine: a novel agent for the treatment of solid tumors

13 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Three distinct signalling responses by murine fibroblasts to genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Chromosome 18q allelic loss and prognosis in stage II and III colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The DCC protein and prognosis in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

A genetic model for colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Colorectal carcinogenesis: from chromosomal evolution pathways to molecular pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Prognostic significance of microsatellite instability in sporadic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Microsatellite Instability in Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Transforming growth factor-beta: multifunctional regulator of differentiation and development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Future potential of thymidylate synthase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Role of biological markers in the clinical outcome of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Thymidylate synthase pharmacogenetics in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Expression of thymidine phosphorylase in human gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

ERCC1: a comparative genomic perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Human xeroderma pigmentosum group D gene encodes a DNA helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The EGF receptor as central transducer of heterologous signalling systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The role of amphiregulin in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro alpha 2 (I) collagen (COL1A2)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

A comparison of selected mRNA and protein abundances in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.6.603

21 January 2018

Identifiers

DOI

10.2217/14622416.6.6.603

1 reference

13 August 2017

1 reference

PubMed ID

16143000